Document is current
Any future updates will be listed below
-
Authors
Leshem, Yael A. https://orcid.org/0000-0001-8740-9674
Weil, Clara https://orcid.org/0000-0002-0174-7208
Busse, William W. https://orcid.org/0000-0003-2591-4696
Beck, Lisa A. https://orcid.org/0000-0003-2649-7863
Chodick, Gabriel https://orcid.org/0000-0002-5189-8995
Cyr, Sonya L. https://orcid.org/0000-0002-7231-0054
Bosman, Kwinten
Lubwama, Robert https://orcid.org/0009-0001-5835-3373
-
Funding
Funding for this research was provided by:
Sanofi and Regeneron Pharmaceuticals Inc.
- License Information
-
More Information
Article History
Received: 15 April 2025
Accepted: 7 August 2025
First Online: 12 September 2025
Declarations
:
: Yael A. Leshem declares consultant and speaker fees from AbbVie, Dexcel Pharma, Eli Lilly, Genentech, Janssen, Pfizer, Regeneron Pharmaceuticals Inc., and Sanofi; has received an independent research grant from AbbVie; and is an investigator without personal compensation for AbbVie, Eli Lilly, Pfizer, and Sanofi. Clara Weil has nothing to declare. William W. Busse is a consultant for and received speaker fees from GSK, Regeneron Pharmaceuticals Inc., and Sanofi. Lisa A. Beck is a consultant for Allakos, Arena Pharmaceuticals, DermTech, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals Inc., Ribon Therapeutics, Sanofi, Stealth BioTherapeutics, Trevi Therapeutics, UNION therapeutics, Xencor; investigator for AbbVie, AstraZeneca, DermTech, Kiniksa Pharmaceuticals, Pfizer, Regeneron Pharmaceuticals Inc., Ribon Therapeutics, and Sanofi. Gabriel Chodick has nothing to declare. Sonya L. Cyr is an employee and shareholder at Regeneron Pharmaceuticals Inc. Kwinten Bosman is an employee and shareholder at Sanofi. Robert Lubwama is an employee at Sanofi and may hold stock and/or stock options in the company.
: The MHS institutional review board approved the study, which was conducted in accordance with the Good Clinical Practice guidelines of the International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use and with the Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects. MHS institutional review board granted a consent waiver owing to the study’s retrospective nature.
